1,888 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Monument Capital Management

Monument Capital Management acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EWGet Rating) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,888 shares of the medical research company’s stock, valued at approximately $222,000.

Other hedge funds have also recently bought and sold shares of the company. American National Bank increased its position in Edwards Lifesciences by 99.1% during the first quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 116 shares during the last quarter. EverSource Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $29,000. Rinkey Investments purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $29,000. Northwest Investment Counselors LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $30,000. Finally, Arlington Partners LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $34,000. Institutional investors and hedge funds own 82.54% of the company’s stock.

In other news, VP Larry L. Wood sold 7,242 shares of Edwards Lifesciences stock in a transaction on Tuesday, April 5th. The stock was sold at an average price of $121.03, for a total transaction of $876,499.26. Following the transaction, the vice president now owns 197,641 shares in the company, valued at approximately $23,920,490.23. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,050 shares of Edwards Lifesciences stock in a transaction on Friday, April 8th. The stock was sold at an average price of $123.34, for a total value of $1,362,907.00. Following the transaction, the vice president now owns 152,326 shares in the company, valued at approximately $18,787,888.84. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 204,165 shares of company stock worth $21,328,796. 1.29% of the stock is currently owned by corporate insiders.

EW traded up $2.92 on Thursday, hitting $93.71. 25,734 shares of the company’s stock were exchanged, compared to its average volume of 2,527,535. Edwards Lifesciences Co. has a fifty-two week low of $85.58 and a fifty-two week high of $131.73. The company has a current ratio of 3.41, a quick ratio of 2.64 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $101.17 and a 200-day moving average price of $110.52. The stock has a market cap of $58.26 billion, a price-to-earnings ratio of 37.21, a P/E/G ratio of 2.51 and a beta of 1.17.

Edwards Lifesciences (NYSE:EWGet Rating) last announced its earnings results on Tuesday, April 26th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.02. Edwards Lifesciences had a net margin of 28.72% and a return on equity of 25.80%. The company had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter in the previous year, the company posted $0.54 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

A number of analysts have recently issued reports on the stock. Citigroup lowered their target price on shares of Edwards Lifesciences from $134.00 to $115.00 and set a “buy” rating for the company in a research note on Tuesday, May 17th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $132.00 to $135.00 in a research report on Wednesday, March 16th. Canaccord Genuity Group cut their target price on shares of Edwards Lifesciences from $152.00 to $137.00 in a report on Wednesday, April 27th. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences in a report on Tuesday, April 26th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, May 5th. Four investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $128.86.

About Edwards Lifesciences (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Further Reading

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.